Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer

G. Ostoros, Klára Szondy, Erzsébet Gergely-Farnos, P. Magyar, J. Strausz, Eniko Ferenczi, Gábor Kovács

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The objective of the study was to assess the efficacy of a gemcitabine and cisplatin combination for patients with stage IIIA"bulky"N2, IIIB or IV non-small cell lung cancer(NSCLC). Patients and Methods: Patients with histological and/or cytological diagnosis of NSCLC were administered gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1, every 3 weeks. Results: One hundred and twenty patients with NSCLC, with median age of 53 years, and a WHO performance status of 0 (26%) or 1 (74%), were evaluated. The overall response rate was 40.0% with 37.5% partial response (PR) and 2.5% complete response (CR). Also, 38% of the patients had either minimal response (MR) or stable disease (SD). The median survival was 54.9 weeks. The time to progression was 28.1 weeks. There was no treatment-related death in this series. CTC grade 3/4 neutropenia occurred in 4.4% of the patients, while febrile neutropenia developed in 0,9% of the patients. CTC grade 4 thrombocytopenia occurred in 2.2%, and CTC grade 3/4 anemia developed in 3.3%. Conclusion: Our results support that gemcitabine and cisplatin administered as a 3-week cycle is an effective and safe regimen for the treatment of locally advanced or metastatic NSCLC.

Original languageEnglish
Pages (from-to)471-475
Number of pages5
JournalAnticancer Research
Volume25
Issue number1 B
Publication statusPublished - Jan 2005

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Therapeutics
Febrile Neutropenia
Neutropenia
Anemia

Keywords

  • Cisplatin
  • Gemcitabine
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer. / Ostoros, G.; Szondy, Klára; Gergely-Farnos, Erzsébet; Magyar, P.; Strausz, J.; Ferenczi, Eniko; Kovács, Gábor.

In: Anticancer Research, Vol. 25, No. 1 B, 01.2005, p. 471-475.

Research output: Contribution to journalArticle

Ostoros, G. ; Szondy, Klára ; Gergely-Farnos, Erzsébet ; Magyar, P. ; Strausz, J. ; Ferenczi, Eniko ; Kovács, Gábor. / Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer. In: Anticancer Research. 2005 ; Vol. 25, No. 1 B. pp. 471-475.
@article{221734f4d59941278c21e40926b3af9b,
title = "Efficacy of gemcitabine-cisplatin treatment in stage IIIA ({"}bulky{"}N2), IIIB and IV non-small cell lung cancer",
abstract = "The objective of the study was to assess the efficacy of a gemcitabine and cisplatin combination for patients with stage IIIA{"}bulky{"}N2, IIIB or IV non-small cell lung cancer(NSCLC). Patients and Methods: Patients with histological and/or cytological diagnosis of NSCLC were administered gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1, every 3 weeks. Results: One hundred and twenty patients with NSCLC, with median age of 53 years, and a WHO performance status of 0 (26{\%}) or 1 (74{\%}), were evaluated. The overall response rate was 40.0{\%} with 37.5{\%} partial response (PR) and 2.5{\%} complete response (CR). Also, 38{\%} of the patients had either minimal response (MR) or stable disease (SD). The median survival was 54.9 weeks. The time to progression was 28.1 weeks. There was no treatment-related death in this series. CTC grade 3/4 neutropenia occurred in 4.4{\%} of the patients, while febrile neutropenia developed in 0,9{\%} of the patients. CTC grade 4 thrombocytopenia occurred in 2.2{\%}, and CTC grade 3/4 anemia developed in 3.3{\%}. Conclusion: Our results support that gemcitabine and cisplatin administered as a 3-week cycle is an effective and safe regimen for the treatment of locally advanced or metastatic NSCLC.",
keywords = "Cisplatin, Gemcitabine, Non-small cell lung cancer",
author = "G. Ostoros and Kl{\'a}ra Szondy and Erzs{\'e}bet Gergely-Farnos and P. Magyar and J. Strausz and Eniko Ferenczi and G{\'a}bor Kov{\'a}cs",
year = "2005",
month = "1",
language = "English",
volume = "25",
pages = "471--475",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Efficacy of gemcitabine-cisplatin treatment in stage IIIA ("bulky"N2), IIIB and IV non-small cell lung cancer

AU - Ostoros, G.

AU - Szondy, Klára

AU - Gergely-Farnos, Erzsébet

AU - Magyar, P.

AU - Strausz, J.

AU - Ferenczi, Eniko

AU - Kovács, Gábor

PY - 2005/1

Y1 - 2005/1

N2 - The objective of the study was to assess the efficacy of a gemcitabine and cisplatin combination for patients with stage IIIA"bulky"N2, IIIB or IV non-small cell lung cancer(NSCLC). Patients and Methods: Patients with histological and/or cytological diagnosis of NSCLC were administered gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1, every 3 weeks. Results: One hundred and twenty patients with NSCLC, with median age of 53 years, and a WHO performance status of 0 (26%) or 1 (74%), were evaluated. The overall response rate was 40.0% with 37.5% partial response (PR) and 2.5% complete response (CR). Also, 38% of the patients had either minimal response (MR) or stable disease (SD). The median survival was 54.9 weeks. The time to progression was 28.1 weeks. There was no treatment-related death in this series. CTC grade 3/4 neutropenia occurred in 4.4% of the patients, while febrile neutropenia developed in 0,9% of the patients. CTC grade 4 thrombocytopenia occurred in 2.2%, and CTC grade 3/4 anemia developed in 3.3%. Conclusion: Our results support that gemcitabine and cisplatin administered as a 3-week cycle is an effective and safe regimen for the treatment of locally advanced or metastatic NSCLC.

AB - The objective of the study was to assess the efficacy of a gemcitabine and cisplatin combination for patients with stage IIIA"bulky"N2, IIIB or IV non-small cell lung cancer(NSCLC). Patients and Methods: Patients with histological and/or cytological diagnosis of NSCLC were administered gemcitabine 1250 mg/m2 on days 1 and 8, and cisplatin 70 mg/m2 on day 1, every 3 weeks. Results: One hundred and twenty patients with NSCLC, with median age of 53 years, and a WHO performance status of 0 (26%) or 1 (74%), were evaluated. The overall response rate was 40.0% with 37.5% partial response (PR) and 2.5% complete response (CR). Also, 38% of the patients had either minimal response (MR) or stable disease (SD). The median survival was 54.9 weeks. The time to progression was 28.1 weeks. There was no treatment-related death in this series. CTC grade 3/4 neutropenia occurred in 4.4% of the patients, while febrile neutropenia developed in 0,9% of the patients. CTC grade 4 thrombocytopenia occurred in 2.2%, and CTC grade 3/4 anemia developed in 3.3%. Conclusion: Our results support that gemcitabine and cisplatin administered as a 3-week cycle is an effective and safe regimen for the treatment of locally advanced or metastatic NSCLC.

KW - Cisplatin

KW - Gemcitabine

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=16344374079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16344374079&partnerID=8YFLogxK

M3 - Article

C2 - 15816614

AN - SCOPUS:16344374079

VL - 25

SP - 471

EP - 475

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -